LGK-974

For research use only. Not for use in humans.

目录号:S7143 别名: NVP-LGK974, WNT974

LGK-974 Chemical Structure

CAS No. 1243244-14-5

LGK-974 (NVP-LGK974, WNT974)是一种有效的特异性PORCN抑制剂,抑制Wnt信号通路,在TM3细胞中IC50为0.4 nM。Phase 1。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 2022.93 现货
RMB 2019.87 现货
RMB 7962.02 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的LGK-974发表文献50篇:

产品安全说明书

PORCN抑制剂选择性比较

生物活性

产品描述 LGK-974 (NVP-LGK974, WNT974)是一种有效的特异性PORCN抑制剂,抑制Wnt信号通路,在TM3细胞中IC50为0.4 nM。Phase 1。
特性 LGK-974是口服有效的Porcupine-特异性抑制剂,用于治疗依赖Wnt配体的恶性肿瘤,目前处于I期临床试验阶段。
靶点
Porcn [1]
(TM3 cells)
体外研究

LGK-974在PORCN放射配体结合测定中,可有效取代[3H]GNF -1331,IC50为1 nM,在细胞中达到20µM时也没有很大的细胞毒作用。LGK974抑制所有测试的Wnts,IC50为0.05到2.4 nM,这与PORCN表型的基因缺失一致。[1] LGK974能特异性地抑制三种RNF43突变细胞株HPAF-II, PaTu 8988S, 和 Capan-2的生长。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HPAF-II  M{DZfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXO4XpQxOSEQvF5CpC=> MXLEUXNQ MlHsbY5pcWKrdIOgeIhmKGe{b4f0bEBw\iCyYX7jdoVifGmlIHPhcoNmeiClZXzsJIxqdmW|IIfpeIjDqFKQRkSzcZV1[XSrb39CpC=> M1zjN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OES3NlA{Lz5{M{i0O|IxOzxxYU6=
PaTu 8988S  NXHrS25JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\PWZIyKM7:TdMg M3jhdGROW09? NVX1SIVbcW6qaXLpeJMhfGinIHfyc5d1cCCxZjDwZY5kemWjdHnjJINidmOncjDj[YxtKGyrbnXzJJdqfGkEoGLOSlQ{dXW2YYTpc47DqA>? M4\NRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OES3NlA{Lz5{M{i0O|IxOzxxYU6=
Capan-2 NITMW25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\PNVEh|ryPwrC= M{XGdGROW09? NV\YZphTcW6qaXLpeJMhfGinIHfyc5d1cCCxZjDwZY5kemWjdHnjJINidmOncjDj[YxtKGyrbnXzJJdqfGkEoGLOSlQ{yqCvdYTheIlwdg>? NGXSW|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0O|IxOyd-MkO4OFczODN:L3G+
HPAF-II M4HnbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWWxJO69VcLi NG\icYNFVVOR MYPpcohq[mm2czD0bIUh\3Kxd4ToJI9nKHCjbnPy[YF1cWNiY3HuZ4VzKGOnbHygcIlv\XNid3n0bOKhWk6INERCpI12fGG2aX;u MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2N{KwN{c,OjN6NEeyNFM9N2F-
PaTu8988S NGnsPY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[2cmQyKM7:TdMg M{GwO2ROW09? M2\PcYlvcGmkaYTzJJRp\SCpcn;3eIghd2ZicHHuZ5Jm[XSrYzDjZY5k\XJiY3XscEBtcW6nczD3bZRpyqCUTl[0N:KhdXW2YYTpc44> MkS1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NEeyNFMoRjJ|OES3NlA{RC:jPh?=
293T  NIrEUI1HfW6ldHnvckBCe3OjeR?= MYDJR|UxyqCxZjCwMlQhdk1idH:gbY5pcWKrdIOgW451KHOrZ37hcIlv\yCrbjD0bIUh[W[xcnXt[Y51cW:wZXSgW451KGOxY4XseJVz\SCjc4PhfS=> MmS1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{N{e4OVQoRjJ2Mke3PFU1RC:jPh?=
293T  NULXWoRwTnWwY4Tpc44hSXO|YYm= MVPJR|UxKG:oIEGgcm0hfG9iY3;tdIV1\SCxZn[gX|NJZS2JTl[tNVM{OSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NF;CXXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK3O|g2PCd-MkSyO|c5PTR:L3G+
HT1080 NV\mOHVOTnWwY4Tpc44h[XO|YYm= MV\Jcohq[mm2aX;uJI9nKHCxcnP1dIlv\SCjY4Tpeol1gSBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDoeY1idiCKVEGwPFAh[2WubIOgZZN{\XO|ZXSgZZMhe3WycILld5Nqd25ib3[gW451O0FvbXXkbYF1\WRic4Xw[ZIhfG:yIH\sZZNpKGGldHn2bZR6KGK7IGPUSkBtfWOrZnXyZZNmKGG|c3H5MEBKSzVyIE2gNE4xODB2IN88UU4> M{j5b|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUKyPVQ3Lz5{NkWyNlk1PjxxYU6=
L Wnt3A, HEK293 NWTrbWJvTnWwY4Tpc44h[XO|YYm= MUS0PEBpenN? M3zKfmlvcGmkaYTpc44hd2ZiV370JJNq\26jbHnu[{ApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBNKFewdEPBJINmdGy|IHPvMYN2dHS3cnXkJJdqfGhiSFXLNlk{KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTeZBmei22b4Cg[oxie2hicnXwc5J1\XJiZ3Xu[UBie3OjeTygTWM2OCB;IECuNFAxQSEQvF2u MnLCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NEezNFMoRjJ4NkS3N|A{RC:jPh?=
L Wnt3A, HEK293 NHHsbVJHfW6ldHnvckBie3OjeR?= NXTqV3VnPDhiaILz MmH1TY5pcWKrdHnvckBw\iCyb4LjeZBqdmViaX6gcY92e2ViTDDXcpQ{SSClZXzsd{Bkdy2ldXz0eZJm\CC5aYToJGhGUzJ7MzDj[YxteyCjZoTldkA1QCCqcoOgZpkhW3WyZYKteI9xKG[uYYPoJJJmeG:{dHXyJIdmdmViYYPzZZktKEmFNUCgQUAxNjByMEmg{txONg>? NEGyTnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{[5NlUxQSd-Mke2PVI2ODl:L3G+
L Wnt3A, HEK293 M2XZNmZ2dmO2aX;uJIF{e2G7 NE\3cZM1QCCqcoO= NEf0S|FKdmirYnn0bY9vKG:oIIDvdoN2eGmwZTDpckBud3W|ZTDMJHdvfDODIHPlcIx{KGOxLXP1cJR2emWmIIfpeIghUEWNMkmzJINmdGy|IHHzd4V{e2WmIHHzJJN2eHC{ZYPzbY9vKG:oIGfueEB{cWewYXzpcoch[W[2ZYKgOFghcHK|IHL5JHN2eGW{LYTvdEBndGG|aDDy[ZBwenSncjDn[Y5mKGG|c3H5MEBKSzVyIE2gNE4xODB7IN88UU4> MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR7OUS4N{c,Ojl2OUm0PFM9N2F-
HEK293T NX;yNnJ1TnWwY4Tpc44h[XO|YYm= NILDdpYxNjFidV2= M3i0R|Q5KGi{cx?= M2DhZ2lvcGmkaYTpc44hd2ZicH;yZ5VxcW6nIDj1cotvd3ewIH;ybYdqdiliaX6gTGVMOjl|VDDj[YxteyC2cnHud4Zm[3SnZDD3bZRpKHCOaXLpck1YVlR|QTDwcIF{dWmmIHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCZboSzRUB{\WO{ZYTpc44hcW62bzDj[YxtKGO3bIT1doUhdWWmaYXtJIF1KDBwMTD1UUBi\nSncjC0PEBpenNiYomgW4V{fGW{bjDicI91KHSnY3jubZF2\Q>? NInpZ249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[0O|MxOyd-Mk[2OFc{ODN:L3G+
HEK293T NHjF[4hHfW6ldHnvckBie3OjeR?= NWmwR|hxOC5zIIXN MlHpOFghcHK| M1L1WmlvcGmkaYTpc44hd2ZicH;yZ5VxcW6nIHnuJGhGUzJ7M2SgZ4VtdHNidILhcpNn\WO2ZXSge4l1cCCyTHnibY4uX06WM1GgdIxie22rZDDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iV370N2Ehe2WlcnX0bY9vKGmwdH:gZ4VtdCCldXz0eZJmKG2nZHn1cUBifCByLkGgeW0h[W[2ZYKgOFghcHK|IHL5JHdme3Sncn6gZoxwfCCvZYToc4Q> MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzZ7MkWwPUc,Ojd4OUK1NFk9N2F-
BT-12 NHS3T4lyUFSVIHHzd4F6 NHf1fZFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO= Mm[4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB1643 M1TLU5FJXFNiYYPzZZk> Mmq5dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?= NYrRRnBWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50 NIfObpdyUFSVIHHzd4F6 NFjBZWFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz NU\qT5BXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC NX\yXIVNeUiWUzDhd5NigQ>? NXnRN3RoeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM> NYrDR4VERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
HEK293 NGjucJVHfW6ldHnvckBie3OjeR?= MWGxNFAhdk1? NITkW3E1QCCqcoO= NHLr[pFKdmirYnn0bY9vKG:oIIDvdoN2eGmwZTDpckBJTUt{OUOgZ4VtdHNidILhcpNn\WO2ZXSge4l1cCCyTHnibY4uX06WM1GgdIxie22rZDDhd5Nme3OnZDDhd{Bld3ewcnXneYxifGmxbjDv[kBNWlB4IIDoc5NxcG:{eXzheIlwdiCjdDCxNFAhdk1iYX\0[ZIhPDhiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= NGjIWII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS5PVQ5Oyd-Mkm0PVk1QDN:L3G+
HEK293T NXPXeYI6TnWwY4Tpc44h[XO|YYm= NVjmNll2OTByIH7N NGTXZo81QCCqcoO= M3;jTGlvcGmkaYTpc44hd2ZicH;yZ5VxcW6nIHnuJGhGUzJ7M2SgZ4VtdHNidILhcpNn\WO2ZXSge4l1cCCyTHnibY4uX06WM1GgdIxie22rZDDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iV370N2Ehe2WlcnX0bY9vKGmwdH:gZ4VtdCCldXz0eZJmKG2nZHn1cUBifCBzMECgcm0h[W[2ZYKgOFghcHK|IHL5JHdme3Sncn6gZoxwfCCvZYToc4Q> MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR7OUS4N{c,Ojl2OUm0PFM9N2F-
PA1 M2DtZmZ2dmO2aX;uJIF{e2G7 MkDmNlQhcHK| NIDxUHpKdmirYnn0bY9vKG:oIIDvdoN2eGmwZT3t[YRq[XSnZDDXcpQw[mW2YT3jZZRmdmmwIIPp[45idGmwZzDpckBpfW2jbjDQRVEh[2WubIOgZZN{\XO|ZXSgZZMh\G:5boLl[5Vt[XSrb36gc4YhSXirbkKgcXJPSSCneIDy[ZN{cW:wIHHmeIVzKDJ2IHjyd{BjgSC{ZXHsMZRqdWViUFPSJIFv[Wy7c3nz NUjDOpJpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0PVk1QDNpPkK5OFk6PDh|PD;hQi=>
HEK293 M1LLU2Z2dmO2aX;uJIF{e2G7 MlPXNVAxKG6P M12xNFQ5KGi{cx?= NFXjWGhKdmirYnn0bY9vKG:oIIDvdoN2eGmwZTDpckBJTUt{OUOgZ4VtdHNidILhcpNn\WO2ZXSge4l1cCCyTHnibY4uX06WM1GgdIxie22rZDDhd5Nme3OnZDDhd{Bld3ewcnXneYxifGmxbjDv[kBlcXOqZY\lcIVlKDJicHjvd5Bpd3K7bHH0bY9vKGG2IEGwNEBvVSCjZoTldkA1QCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| NXvRSmJXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0PVk1QDNpPkK5OFk6PDh|PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-LRP6 / Axin / p-GSK3β / p-β-catenin / β-catenin; 

PubMed: 28128299     


BEAS-2B human bronchial epithelial cells were pretreated with 0.001–10 nM of LGK974 for 2 hours, followed by 0.1 μg/ml of LPS stimulation for 2 hours.

NF-κB / IκB / p-IκB; 

PubMed: 28128299     


BEAS-2B human bronchial epithelial cells were pretreated with 0.001–10 nM of LGK974 for 2 hours, followed by 0.1 μg/ml of LPS stimulation for 2 hours. Western blotting was used to assess protein levels and phosphorylation of NF-κB and IκB.

Nrf2 / Wnt3A / HO-1 / NQO-1 / Survivin; 

PubMed: 28627706     


HepG2 cells were treated with LGK-974 at the indicated concentrations and collected after 24 h. Then, we extracted total protein samples for western blot analysis.

28128299 28627706
Immunofluorescence
beta-catenin; 

PubMed: 25639201     


HTM cells treated with 10 μM KY02111 or LGK-974 likewise show a reduction of β-catenin staining intensity.

FUT8; 

PubMed: 28798691     


Representative immunofluorescent and Lectin fluorescent images of FUT8 (Scale bars = 50 μm; Magnification, 400×). 

α1, 6-fucosylation ; 

PubMed: 28798691     


Representative immunofluorescent and Lectin fluorescent images of α1, 6-fucosylation. (Scale bars = 50 μm; Magnification, 400×). 

25639201 28798691
体内研究 LGK-974 (3 mg/kg)作用于小鼠MMTV-WNT1肿瘤模型和人的头部和颈部鳞状细胞癌模型(hn30),抑制 Wnt 信号通路,诱导肿瘤退化且小鼠体重没有明显的下降。[1] LGK-974 (5 mg/kg, p.o., BID) 也能抑制RNF43-突变胰腺肿瘤(HPAF-II 和Capan-2)的生长。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[2]
- 合并
  • Cell lines: HPAF-II, PaTu 8988S, 和 Capan-2 细胞
  • Concentrations: ~1 μM
  • Incubation Time: 3 天
  • Method: 细胞以每份密度6,000–12,000个接种在96孔板上,加入 DMSO或1 μM LGK974的培养基培养。3天后,加入新鲜的含有20 μM EdU的培养液,EdU来自Click-iT EdU Alexa Fluor 488 HCS试剂盒,孔板在37°C含有5% CO2的湿润空气温育2小时。用4% (mass/vol) paraformaldehyde固定细胞30分钟,用PBS清洗,渗透,然后用50 μg/mL溶于PBS的Hoechst 染色30分钟。清洗后,根据Click-iT EdU试剂盒的说明检测。在每种条件下每孔进行一式三份。
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: 小鼠MMTV-Wnt1肿瘤模型和人体头颈部鳞状细胞癌模型(HN30)
  • Dosages: ~3 mg/kg 每天
  • Administration: 口服灌胃
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 79 mg/mL warmed (199.27 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+corn oil
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 396.44
化学式

C23H20N6O

CAS号 1243244-14-5
储存条件 粉状
溶于溶剂
别名 NVP-LGK974, WNT974

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01351103 Recruiting Drug: LGK974|Biological: PDR001 Pancreatic Cancer|BRAF Mutant Colorectal Cancer|Melanoma|Triple Negative Breast Cancer|Head and Neck Squamous Cell Cancer|Cervical Squamous Cell Cancer|Esophageal Squamous Cell Cancer|Lung Squamous Cell Cancer Novartis Pharmaceuticals|Novartis December 1 2011 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    If LGK974 is a lipophilic or hydrophilic substance?

  • 回答:

    LGK974 is a lipophilic compound.

Tags: 购买LGK-974 | LGK-974供应商 | 采购LGK-974 | LGK-974价格 | LGK-974生产 | 订购LGK-974 | LGK-974代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID